PMID- 35526777
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20230224
IS  - 2213-2201 (Electronic)
IS  - 2213-2198 (Print)
VI  - 10
IP  - 7
DP  - 2022 Jul
TI  - Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, 
      Prevent, and Diagnose Drug Hypersensitivity.
PG  - 1689-1700
LID - S2213-2198(22)00471-8 [pii]
LID - 10.1016/j.jaip.2022.04.027 [doi]
AB  - Delayed drug hypersensitivities are CD8(+) T cell-mediated reactions associated 
      with up to 50% mortality. Human leukocyte antigen (HLA) alleles are known to 
      predispose disease and are specific to drug, reaction, and patient ethnicity. 
      Pretreatment screening is recommended for a handful of the strongest associations 
      to identify and prevent drug use in high-risk patients. However, an incomplete 
      predictive value implicates other HLA-imposed risk factors, and low carriage of 
      many identified HLA-risk alleles combined with the high cost of sequence-based 
      typing has limited economic viability for similar recommendation of screening 
      across drugs and health care systems. For mitigation, an expanding armory of 
      low-cost polymerase chain reaction-based screens is being developed, and 
      HLA-imposed risk factors are being discovered. These include (1) polymorphic 
      variants of metabolic and endoplasmic reticulum aminopeptidase enzymes toward 
      multiallelic screening with increased predictivity; (2) regulation by immune 
      checkpoint inhibitors, enabling detolerized animal models of human disease; and 
      (3) immunodominant T cell receptors (TCR) on clonally expanded CD8(+) T cells. 
      For the latter, HLA risk-restricted TCR provides immunogenomic strategies and 
      samples from a single patient to identify novel HLA-risk associations in 
      underserved minority populations, tissue-relevant effector biomarkers toward 
      earlier diagnosis and treatment, and HLA-TCR-presented immunogenic structures to 
      aid future drug development.
CI  - Copyright (c) 2022 American Academy of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Deshpande, Pooja
AU  - Deshpande P
AD  - Institute for Immunology and Infectious Disease, Murdoch University, Perth, 
      Western Australia, Australia.
FAU - Li, Yueran
AU  - Li Y
AD  - Institute for Immunology and Infectious Disease, Murdoch University, Perth, 
      Western Australia, Australia.
FAU - Thorne, Michael
AU  - Thorne M
AD  - Institute for Immunology and Infectious Disease, Murdoch University, Perth, 
      Western Australia, Australia.
FAU - Palubinsky, Amy M
AU  - Palubinsky AM
AD  - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
FAU - Phillips, Elizabeth J
AU  - Phillips EJ
AD  - Institute for Immunology and Infectious Disease, Murdoch University, Perth, 
      Western Australia, Australia; Department of Medicine, Vanderbilt University 
      Medical Center, Nashville, Tenn.
FAU - Gibson, Andrew
AU  - Gibson A
AD  - Institute for Immunology and Infectious Disease, Murdoch University, Perth, 
      Western Australia, Australia. Electronic address: a.gibson@iiid.murdoch.edu.au.
LA  - eng
GR  - P50 GM115305/GM/NIGMS NIH HHS/United States
GR  - R01 HG010863/HG/NHGRI NIH HHS/United States
GR  - U01 AI154659/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20220506
PL  - United States
TA  - J Allergy Clin Immunol Pract
JT  - The journal of allergy and clinical immunology. In practice
JID - 101597220
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - *CD8-Positive T-Lymphocytes
MH  - *Drug Hypersensitivity/diagnosis/genetics
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Receptors, Antigen, T-Cell
PMC - PMC9948495
MID - NIHMS1870658
OTO - NOTNLM
OT  - Drug hypersensitivity
OT  - Endoplasmic reticulum aminopeptidase
OT  - Human leukocyte antigen
OT  - Immunogenomics
OT  - Single-cell sequencing
OT  - T cell receptor
COIS- Conflict-of-interest disclosure statement: All authors declare no conflict of 
      interest.
EDAT- 2022/05/09 06:00
MHDA- 2022/07/14 06:00
PMCR- 2023/02/23
CRDT- 2022/05/08 19:26
PHST- 2022/01/11 00:00 [received]
PHST- 2022/04/26 00:00 [revised]
PHST- 2022/04/26 00:00 [accepted]
PHST- 2022/05/09 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/05/08 19:26 [entrez]
PHST- 2023/02/23 00:00 [pmc-release]
AID - S2213-2198(22)00471-8 [pii]
AID - 10.1016/j.jaip.2022.04.027 [doi]
PST - ppublish
SO  - J Allergy Clin Immunol Pract. 2022 Jul;10(7):1689-1700. doi: 
      10.1016/j.jaip.2022.04.027. Epub 2022 May 6.